A new drug for pulmonary hypertension, (PAH) Sotatercept, has just been approved. PAH is not a typical MPN worry, but it has side effects that may be relevant to MPN. It can increase Hb and decrease PLT. These are listed as adverse effects in the label.
Some researchers made the MPN connection. In this phase 2 trial they found some MF pts had a benefit for anemia. This could allow MF pts to stay on Rux for longer, esp those not requiring transfusions. Strangely they did not track PLT at all.
ashpublications.org/blood/a...
"Sotatercept is safe and effective against anemia of MPN-associated MF, both in non-TD and TD pts, with a response rate of 30% when used alone and 32% when used in conjunction with a stable dose of rux. All responses in the rux cohort occurred in non-TD (transfusion dependent) pts. "
Its other side effect "Severe Thrombocytopenia" could be useful for ET pts who are not responding to other options.
accessdata.fda.gov/drugsatf...
Not likely useful to PV given the Hb effect, but the wording of the label implies the PLT effect is esp strong. The ET application is intriguing since there are no good solutions for PLT reduction beyond the familiar agents we know. But there are no studies I can find on this use.
It would be off label for MF and ET, but at least the MF indication has evidence of effectiveness, so insurance might pay.
I learned of this from the Sjogren's forum where PAH is often seen. But the MPN connection came to mind.